Get Involved

Participate in a Research Study

The Clinical Research Unit serves as a place where basic and clinical scientists work together to perform studies that incorporate translational research (the process of making research findings benefit patients) resulting in meaningful health outcomes. The Clinical Research Unit, along with skilled researchers and coordinators, will provide a welcoming and proficient setting for participants to volunteer in groundbreaking research studies.

Volunteering for clinical trials may someday benefit you or someone you know since you will be contributing to the development of the new and innovative treatments being investigated at the Alberta Diabetes Institute.

Contact the CRU

Interested in participating in research, but don’t qualify for any of our current studies? 
Contact us about participation in future research studies at the Alberta Diabetes Institute.


Currently Recruiting

Biomedical

  • Genetic Testing of Obese Children and Adults

    - Andrea Haqq

    Genes are often called “DNA” and are found in the body, making every individual different from anyone else. Some genes control things like the color of the hair or eyes. Other genes might make people more likely to weigh more.

    The purpose of this study is to identify people who have a rare genetic cause of obesity, who are 2 years of age or older.

    Participants will come to the University of Alberta for a one-hour visit.

    Participants will be asked questions about their health and appetite. Next, we will collect a blood sample from their arm. This screening test will identify individuals with one of three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that is currently known to result in obesity.

    Sponsored by Rhythm Pharmaceuticals, Inc.

    Inclusion criteria:

    • Evidence of hunger/hyperphagia at screening

    • Severe childhood obesity, preferably with past history evidence suggestive of onset prior to age 6 years at the time of identification

    For more information please contact: Lucila at triador@ualberta.ca

    Sponsored by Rhythm Pharmaceuticals, Inc.

  • NN9828-4150 Study

    Effect of NNC0114-006 and liraglutide on preservation of beta cell function in adults with newly diagnosed Type 1 diabetes

    —Peter Senior/Novo Nordisk

    Phase 2 drug trial for patients who have been newly diagnosed with Type 1 diabetes (within the past 5 months)

    Contact the ADI Clinical Research Unit for more information or for prescreening:

    Amanda Perreault

    780-492-1098
    adicru@ualberta.ca

    Caroline Lyster

    780-­492-1098
    clyster@ualberta.ca

  • Once weekly growth hormone therapy

    - Dr. Andrea Haqq

    Researchers at the University of Alberta are investigating whether a new type of growth hormone therapy that is injected once a week is as safe and effective as the standard daily injection of growth hormone that is normally used to treat children with Growth Hormone Deficiency.

    Sponsored by OPKO Biologics

    Requirements:

    • between the age of 3-10 years (for girls), or 3-11 years (for boys)
    • has growth failure due to growth hormone deficiency


    For more information, please contact:


    Kristie DeHann

    780-492-1098
    adiCRU@ualberta.ca

    Caroline Lyster
    780-­248-­1770
    clyster@ualberta.ca


  • ONSET 9

    - Dr. Peter Senior

    Researchers are investigating whether a new faster-acting insulin is able to control blood sugar levels more effectively than NovoRapid in patients with Type 2 Diabetes.

    Sponsored by Novo Nordisk

    You may qualify for the study if:

    • Have had type 2 diabetes for at least 10 years
    • Have been using basal-bolus insulin for more than 1 year
    • Have an HbA1c between 7.0% - 10.0%


    For more information, please contact:


    Kristie DeHann

    780-492-1098
    adiCRU@ualberta.ca

    Caroline Lyster
    780-­248-­1770
    clyster@ualberta.ca


  • PBI-4050-CT-9-08: A study for adults who have Type 2 diabetes with metabolic syndrome

    - Dr. Peter Senior

    This research study is investigating whether or not an investigational drug can improve blood sugar control and the general health of people who have Type 2 diabetes with metabolic syndrome.

    Sponsored by ProMetic Pharma SMT Ltd

    You may qualify for the study if:

    • You have Type 2 diabetes
    • You are taking oral medication for your diabetes, and/or are using long-acting insulin
    • You have any of the following:

    - Abdominal obesity (large waist)
    - High triglycerides
    - Low HDL-C (“good” cholesterol)
    - High blood pressure
    - High fasting blood sugar


    For more information, please contact:


    Kristie DeHann

    780-492-1098
    adiCRU@ualberta.ca

    Caroline Lyster
    780-­248-­1770
    clyster@ualberta.ca

Nutrition

Physical Activity